Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

NLRP3 inhibitors stoke anti-inflammatory ambitions

Inhibitors of the innate immune system’s NLRP3 inflammasome promise potential in Parkinson disease, Alzheimer disease, non-alcoholic steatohepatitis, gout and much more, catching the eye of Novartis, Genentech and others.
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed  Google Scholar

Credit: S.Harris/Springer Nature Limited

With Novartis’s April acquisition of IFM Tre for US$310 million upfront plus future milestone payments, the innate immune system’s NLRP3 target continues to excite industry interest.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 18, 405-407 (2019)

doi: https://doi.org/10.1038/d41573-019-00086-9

Updates & Corrections

  • Clarification 24 May 2019: The article has been updated to provide further detail on early work on NLRP3 inhibitors, which included a 2009 paper in the Journal of Cell Biology by Genentech's Vishva Dixit and colleagues.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links